Vyome narrows Q3 loss to $0.13 per share, cash rises to $7M

Vyome Holdings (NASDAQ:HIND) reported a narrower Q3 loss of $0.13 per share, down from $3.06 a year ago. Revenue increased to $57,998 from $34,627, but nine-month revenue fell to $116,544. Cash rose to $6.96M. Operating expenses decreased to $1.05M. The company is developing VT-1953 and appointed a new CFO. The FDA requested more info on its orphan drug designation.

Original reporting
Published Nov 16, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HIND
Neutral
medium confidence
Mentioned
$HIND
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HINDNeutralMed
01

Why it matters

The earnings release provides the first detailed financial snapshot for Q3 2026, highlighting a significant loss reduction but continued cash constraints.

02

Market read

Micro‑cap biotech earnings with modest loss improvement; limited immediate market impact but relevant for sector‑focused traders.

03

What to watch

Potential FDA meeting and orphan‑drug designation progress could be catalysts not reflected in the earnings numbers.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Vyome Holdings is a clinical‑stage biopharma developing topical treatments for rare wound conditions.

Company-level read

Ticker impact

$HINDNeutralMedium confidence
Context

Vyome Holdings reported Q3 loss of $0.13 per share, cash $6.96M and revenue $58K, a fresh earnings release for the company.

Expected impact

likely modest upside as the loss narrowed, but limited by low revenue and cash constraints

Evidence & confidence

Quarterly loss improvement is positive, yet the company remains cash‑light and revenue‑poor, suggesting only a small price move.

Market effects

Biopharma micro‑caps may see slight attention as earnings season highlights cash‑flow challenges.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; only relevant to niche biotech investors.

Counterpoint

Despite loss narrowing, the company’s tiny revenue and cash burn could trigger further downside.

Key entities

  • Vyome Holdings, Inc.

    Clinical‑stage biopharma reporting Q3 2026 results.

  • Jerry Leonard

    Newly appointed Chief Financial Officer.

Related articles

HighAI 8/10

Vyome at Chardan healthcare conference: lean biotech bets on rare wounds

Vyome Therapeutics (HIND) presented its strategy at Chardan's healthcare conference, focusing on VT-1953, a topical gel for malignant fungating wounds. The company reported Q2 operating expenses of $874,000 and shared encouraging early data from a Phase II study. Vyome aims to conserve capital and targets rare diseases with unmet needs, engaging with the FDA for further discussions.

$HINDHigh

Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet

Vyome Holdings, Inc (HIND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 — Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused o

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.